Japan Software as a Medical Device Market to Reach USD 96.20 Million by 2033 as AI Diagnostics, Digital Therapeutics, and Remote Monitoring Move Into Scaled Clinical Adoption

Austin, Texas and Tokyo, Japan, May 2026 - DataM Intelligence has released its latest research report on the Japan Software as a Medical Device Market, identifying a high-growth opportunity for AI healthcare companies, medical device software developers, diagnostic imaging vendors, digital therapeutic companies, remote monitoring platforms, cloud healthcare providers, hospitals, pharmaceutical companies, and Japan-USA digital health businesses.

According to DataM Intelligence, the Japan Software as a Medical Device Market reached USD 22.93 million in 2025 and is expected to reach USD 96.20 million by 2033, growing at a CAGR of 17.3% during 2026 to 2033. This represents an incremental revenue opportunity of USD 73.27 million, with the market expanding more than 4.19 times from its 2025 level. The market is segmented by application into disease management, diagnostics, treatment monitoring, predictive health analytics, and others, and by indication into diabetes, mental health, oncology, cardiovascular, respiratory conditions, and others.

The commercial direction is clear: SaMD in Japan is moving from experimental digital health toward regulated, evidence-backed, clinically integrated software. The strongest growth opportunities are expected in AI-assisted diagnostics, imaging support, chronic disease management, remote monitoring, treatment decision support, and predictive analytics. For healthcare companies targeting Japan and the USA, SaMD is becoming a scalable route to deliver medical value without the manufacturing burden of traditional hardware-based devices.

Request Executive Sample | Market Intelligence: https://www.datamintelligence.com/download-sample/japan-software-as-a-medical-device-market?kailas

Market Outlook: From USD 22.93 Million in 2025 to USD 96.20 Million by 2033

The Japan SaMD market is projected to grow by approximately 319.54% between 2025 and 2033. Based on the reported CAGR of 17.3%, the market is estimated to move from USD 22.93 million in 2025 to approximately USD 26.90 million in 2026, USD 31.55 million in 2027, USD 37.00 million in 2028, USD 43.40 million in 2029, USD 50.91 million in 2030, USD 59.72 million in 2031, USD 70.06 million in 2032, and USD 96.20 million by 2033.

This growth is being driven by a structural change in Japan's healthcare system. Hospitals need software that can improve diagnostic speed, reduce workload pressure, support specialist shortages, and extend care beyond hospital walls. Patients need digital tools that can help manage chronic disease, treatment adherence, remote monitoring, and preventive intervention. Regulators are also creating clearer commercialization pathways for software-based medical products.

The U.S. International Trade Administration notes that Japan has been actively undertaking measures to improve the regulatory review process for medical device software and SaMD. It also states that Japan historically trailed the U.S. and Europe in therapeutic app approvals, with only three therapeutic apps approved in Japan as of September 2023, compared with more than 50 in the U.S. and Europe. This gap creates a strong catch-up opportunity for domestic and international SaMD developers.

Regulatory Reform Is Becoming a Direct Market Catalyst

Japan's SaMD market is being supported by regulatory modernization. MHLW introduced DASH for SaMD 2 in September 2023 to promote practical application and international development of SaMD. The strategy includes organizing and publicizing a two-step approval scheme, developing guidelines for approval review and marketing procedures, promoting overseas acceptance of Japanese review results, providing development subsidies, and supporting overseas business expansion by SaMD developers.

The U.S. International Trade Administration also highlights that Japan's two-stage approval system is intended to grant initial approval for limited intended uses based on software performance, with a second-stage approval possible after additional evidence and real-world data are gathered. It also notes that PMDA's draft fifth mid-term plan for JFY 2024 to JFY 2028 introduced a target review timeframe of six months for SaMD products undergoing priority review.

This is commercially important because SaMD business models depend on faster iteration than traditional medical devices. A more predictable review pathway can reduce time-to-market risk, improve investor confidence, encourage clinical partnerships, and support post-market performance improvement through real-world evidence.

Detailed Segmentation Analysis
By Application: Diagnostics Dominates Because Japan Needs Faster, More Accurate Clinical Decision Support

By application, the market is segmented into disease management, diagnostics, treatment monitoring, predictive health analytics, and others. DataM Intelligence identifies diagnostics as the segment expected to dominate the Japan SaMD market with the highest market share. The report states that the diagnostics segment is driven by early disease detection, chronic conditions, AI-driven imaging, data analytics, remote diagnostics, telemedicine expansion, regulatory approvals for AI-powered tools, and cloud-based platforms.

Diagnostics is estimated to account for approximately 37.5% of the market in 2025, equal to nearly USD 8.60 million. By 2033, diagnostics is projected to reach approximately USD 39.44 million, representing about 41.0% of the total market. The segment dominates because diagnostic software delivers a direct hospital outcome: faster image interpretation, improved clinical workflow, earlier disease detection, and better specialist productivity.

AI imaging is a key driver. DataM Intelligence cites the January 2025 partnership between Monitor Corporation, a Korean medical AI company, and Japanese digital healthcare provider Doctor-NET to sell MONCAD CTLN, an AI-powered lung cancer diagnosis software using chest CT scans, in Japan. The report states that Doctor-NET obtained manufacturing and sales certification for the software in Japan.

By Application: Disease Management Gains Value From Diabetes, Mental Health, and Chronic Care

Disease management is estimated to account for approximately 24.0% of the market in 2025, equal to about USD 5.50 million. By 2033, the segment is expected to reach nearly USD 23.09 million. This segment includes regulated software that supports chronic disease management, patient engagement, risk tracking, behavioral intervention, and clinical decision support.

Disease management is commercially attractive because Japan's aging population increases the burden of chronic disease, while hospitals and clinics need more scalable ways to manage patients outside traditional visits. The strongest disease management opportunities are expected in diabetes, mental health, cardiovascular risk, respiratory conditions, and medication-linked care programs.

The Japan Pharmaceutical Manufacturers Association notes that digital health products such as SaMD and digital biomarkers are becoming increasingly active in healthcare, and that the pharmaceutical industry is considering and developing SaMD as part of healthcare services centered on pharmaceuticals or as new treatment modalities that may replace pharmaceuticals in some cases.

By Application: Treatment Monitoring and Predictive Health Analytics Expand With Remote Care

Treatment monitoring is estimated to hold approximately 18.0% of the market in 2025, equal to nearly USD 4.13 million, and is projected to reach approximately USD 17.32 million by 2033. This segment is growing because SaMD can help monitor patient progress, identify treatment response, support medication adherence, track symptoms, and alert clinicians when clinical deterioration is likely.

Predictive health analytics is estimated to account for approximately 13.0% of market value in 2025, equal to about USD 2.98 million, and is expected to reach approximately USD 13.47 million by 2033. This is one of the faster-growing application areas because AI and machine learning can turn clinical data, imaging data, patient-generated data, and real-world evidence into risk prediction, triage support, and personalized care recommendations.

By Indication: Diabetes and Cardiovascular Lead Clinical Demand, Oncology and Mental Health Grow Faster

By indication, the market is segmented into diabetes, mental health, oncology, cardiovascular, respiratory conditions, and others.

Diabetes is estimated to account for approximately 24.5% of the market in 2025, equal to nearly USD 5.62 million. By 2033, diabetes-related SaMD is expected to reach approximately USD 22.13 million. Diabetes dominates because software can support glucose monitoring, medication adherence, lifestyle intervention, risk alerts, and clinician-led remote management.

Cardiovascular indications are estimated at approximately 20.0% share in 2025, equal to USD 4.59 million, and are projected to reach nearly USD 19.24 million by 2033. This segment is attractive because cardiovascular care benefits from remote monitoring, risk scoring, diagnostic support, arrhythmia detection, cardiac imaging software, and rehabilitation-linked digital tools.

Oncology is estimated to account for approximately 17.0% share in 2025, equal to USD 3.90 million, and is expected to reach around USD 18.28 million by 2033. Oncology is one of the fastest-growing indications because AI-enabled imaging, pathology support, tumor monitoring, treatment planning, and early detection software can create measurable clinical value.

Mental health is estimated at approximately 16.0% share in 2025, equal to USD 3.67 million, and is projected to reach approximately USD 16.35 million by 2033. This segment is commercially important because digital therapeutics and regulated software can improve access, continuity, and structured behavioral support.

Respiratory conditions are estimated to represent approximately 11.5% of the market in 2025, equal to USD 2.64 million, and are projected to reach nearly USD 10.58 million by 2033. Respiratory SaMD demand is linked to remote monitoring, lung imaging support, COPD management, asthma management, sleep-related conditions, and post-acute monitoring.

Competitive Landscape and Company Profiles
Japan Medical Device Corporation

Japan Medical Device Corporation is listed by DataM Intelligence as one of the major players in the Japan SaMD market. Its relevance comes from Japan's growing need for regulated software products that can support diagnosis, treatment, monitoring, clinical workflows, and patient outcomes.

The company's strongest market opportunity is likely to be linked to Japan-specific regulatory understanding, domestic clinical partnerships, localization, and SaMD commercialization pathways. In a market where PMDA review, clinical evidence, reimbursement predictability, and post-market performance monitoring are critical, domestic players with Japan-focused regulatory and clinical execution capabilities can gain meaningful advantage.

Nipro Corporation

Nipro Corporation is identified by DataM Intelligence as a key player in the Japan SaMD market. Nipro's broader positioning as a Japan-based healthcare and medical device company gives it relevance in digital medical solutions that can connect patient monitoring, hospital workflows, device ecosystems, and chronic care.

Nipro's opportunity in SaMD is strongest where software can be paired with device-based care, renal care, infusion, diabetes-related monitoring, hospital-based medical workflows, and patient support platforms. For Japanese hospitals and clinics, integrated solutions that combine trusted medical device infrastructure with compliant software can reduce adoption friction.

Olympus Medical Systems

Olympus Medical Systems is also identified by DataM Intelligence as a major Japan SaMD market player. Olympus has a strong medical technology base in endoscopy and therapeutic solutions. Its annual securities report states that Olympus is primarily engaged in manufacturing and selling endoscopic, therapeutic, and other products, and identifies Olympus Medical Systems Corp. among its major medical business companies.

Olympus' relevance to SaMD is linked to intelligent endoscopy, imaging support, digital workflow enhancement, and clinical decision support. Olympus' Integrated Report 2024 highlights "Intelligent Endoscopy Ecosystem" as one of the strategic value pools driving long-term growth. This positions the company well for software-enabled diagnostic support, procedure support, and data-connected medical workflows.

Anaut Inc.

Anaut is one of the most relevant Japan-originated SaMD innovators because it focuses on AI-powered surgical support. NEDO describes Anaut's research theme as the integration of surgical support AI technology with next-generation medical devices and global expansion. NEDO also states that the company aims to implement AI and other advanced technologies in the operating room, improve qualitative and quantitative accuracy, conduct demonstration tests, and pursue overseas expansion activities.

NEDO lists Anaut's Deep-Tech Startups Support Program research period as FY2023 to FY2025, with a research grant amount of JPY 299 million, and identifies Japan, the United States, and Europe as regions for international collaborative technology demonstration. Anaut is strategically important because surgical support SaMD can improve intraoperative visualization, surgeon workflow, and procedure safety.

Recent Developments
1. Japan Advanced DASH for SaMD 2 to Improve Commercialization Predictability

MHLW compiled DASH for SaMD 2 in September 2023 to promote practical application and international development of SaMD. The strategy includes two-step approval organization, public guidance for review and marketing procedures, development subsidies, overseas expansion support, and improved post-marketing performance enhancement.

This is one of the most important policy developments for the market because it directly addresses time-to-approval, evidence generation, and commercialization uncertainty.

2. PMDA Set Direction for Dedicated SaMD Review Infrastructure

The U.S. International Trade Administration reported that PMDA's JFY 2024 to JFY 2028 draft fifth mid-term plan includes a target review timeframe of six months for SaMD products under priority review, along with organizational restructuring to incorporate a department dedicated to SaMD review and a new consultation category for improved guidance.

This supports market growth by giving SaMD developers a clearer route to regulatory engagement, especially for AI diagnostics, digital therapeutics, monitoring software, and clinical decision support tools.

3. AI Lung Cancer Diagnostic Software Entered Japan Through Monitor and Doctor-NET Partnership

DataM Intelligence reports that in January 2025, Monitor Corporation partnered with Doctor-NET to sell MONCAD CTLN, an AI-powered lung cancer diagnosis software using chest CT scans, in Japan, and that Doctor-NET obtained manufacturing and sales certification for the software.

This development strengthens the diagnostics segment and shows how international AI software companies can enter Japan through local digital healthcare partners with regulatory and commercialization capabilities.

4. Anaut Received Government-Backed Support for Surgical AI and Global Expansion

NEDO lists Anaut under its Deep-Tech Startups Support Program, with a research theme focused on surgical support AI technology, next-generation medical device integration, and global expansion. The program includes a JPY 299 million grant across FY2023 to FY2025 and includes planned activity across Japan, the United States, and Europe.

This development is important because it shows government-backed support for Japan-originated SaMD companies targeting operating room AI and international market development.

5. Pharmaceutical Industry Participation in SaMD Development Is Increasing

JPMA states that digital health products such as SaMD and digital biomarkers are becoming increasingly active in healthcare, and that pharmaceutical companies are considering SaMD as part of healthcare services centered on pharmaceuticals or as new treatment modalities that can replace pharmaceuticals.

Purchase Corporate License | Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=japan-software-as-a-medical-device-market?kailas

Why This Market Matters for Japan and USA-Focused Businesses

The Japan SaMD market is attractive because it combines high growth, regulatory reform, clinical unmet need, and global partnership potential. The market is expected to grow from USD 22.93 million in 2025 to USD 96.20 million by 2033, adding USD 73.27 million in new value.

For Japan-based companies, the strongest opportunities are in AI diagnostics, diabetes management software, oncology imaging support, cardiovascular monitoring, mental health digital therapeutics, hospital workflow software, and surgical support tools. Companies that can prove clinical utility, regulatory compliance, cybersecurity readiness, and workflow fit will be better positioned to convert hospital adoption into recurring software revenue.

For USA-focused companies, Japan offers a meaningful entry opportunity because regulators are actively improving SaMD commercialization pathways, and Japan still has room to catch up with the U.S. and Europe in therapeutic app approvals. U.S. companies with strong clinical evidence, FDA experience, AI imaging capability, remote monitoring tools, or digital therapeutics platforms can benefit from Japan's evolving review environment, especially through local partnerships.

Conclusion

The Japan Software as a Medical Device Market is projected to reach USD 96.20 million by 2033, growing at a 17.3% CAGR and creating USD 73.27 million in new value from 2025 levels. Diagnostics is expected to remain the leading application, while disease management, treatment monitoring, predictive health analytics, oncology, diabetes, cardiovascular, and mental health applications are expected to generate high-value growth.

The market's growth is being driven by measurable outcomes: faster diagnosis, improved clinical decision support, chronic disease management, remote patient monitoring, reduced hospital workload, and more predictable regulatory pathways. Companies that can deliver clinically validated, PMDA-ready, workflow-integrated, and scalable SaMD solutions will be best positioned to capture Japan's next phase of digital healthcare growth.

Contact:
Fabian
DataM Intelligence 4market Research LLP
6th Floor, M2 Tech Hub, DataM Intelligence 4market Research LLP, Lalitha Nagar, Habsiguda, Secunderabad, Hyderabad, Telangana 500039
USA: +1 877-441-4866
UK: +44 161-870-5507
Email: fabian@datamintelligence.com

About DataM Intelligence

DataM Intelligence provides market research and consulting insights across high-growth industries, helping organizations evaluate market size, competitive positioning, regulatory impact, customer demand, partner opportunities, and investment priorities. Its research supports business planning, market entry, product development, and strategic decision-making across global markets.

This release was published on openPR.